Comments on: Kayothera, Inc. Nominates KAYO-1732, a First-In-Class, Oral Inhibitor of the Retinoid Nuclear Receptor Pathway in Type 2 Diabetes and Cardiometabolic Indications as a Development Candidate

Comments on: Kayothera, Inc. Nominates KAYO-1732, a First-In-Class, Oral Inhibitor of the Retinoid Nuclear Receptor Pathway in Type 2 Diabetes and Cardiometabolic Indications as a Development Candidate https://kayothera.com/kayothera-inc-nominates-kayo-1732-a-first-in-class-oral-inhibitor-of-the-retinoid-nuclear-receptor-pathway-in-type-2-diabetes-and-cardiometabolic-indications-as-a-development-candidate/ Mon, 22 Sep 2025 22:36:26 +0000 hourly 1 https://wordpress.org/?v=6.9.1